AstraZeneca Pharma India Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Excellent return on equity (ROE 22.8%)
- ✓Low debt relative to equity (D/E 0.1x)
Concerns
- ✗Premium to sector peers (P/E 116x vs industry 54.4x)
- ✗High premium to book value (P/B 25x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ASTRAZEN · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FII | 2.66% | 2.73% | 2.79% | 2.90% | 2.92% | 2.89% |
| DII | 2.76% | 3.77% | 4.99% | 5.08% | 5.21% | 4.65% |
| Public | 19.57% | 18.50% | 17.21% | 17.02% | 16.85% | 17.45% |
Corporate Events
Dividend - Rs 36 Per Share
Dividend - Rs 32 Per Share
Dividend - Rs 24 Per Share
Dividend - Rs 16 Per Share
Latest News
All news →AstraZeneca Pharma India issues general updates
*AstraZeneca Pharma India issues general updates.* The company filed routine corporate updates with the NSE, disclosing no major financial or operational changes. Details remain unspecified in the filing. Such announcements typically have minimal market impact. 📊 *STOCKS:* ASTRAZEN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporate
AstraZeneca Pharma India issues general corporate update
*AstraZeneca Pharma India issues general corporate update.* The company filed a routine disclosure on the NSE with no specific financial or operational details. Such updates typically involve internal administrative or compliance matters. No immediate market-moving information was disclosed. 📊 *STOCKS:* ASTRAZEN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateUpdate
AstraZeneca Pharma India issues general updates.
*AstraZeneca Pharma India issues general updates.* The company filed routine corporate updates on the NSE without disclosing specific financial or operational details. Such filings typically include administrative or compliance-related information. No material developments were indicated. 📊 *STOCKS:* ASTRAZEN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
AstraZeneca Pharma India's earnings face underlying issues
*AstraZeneca Pharma India's earnings face underlying issues*\nRecent analysis suggests potential weaknesses in AstraZeneca Pharma India's earnings quality. Despite reported numbers, concerns remain over sustainability and operational performance. The company’s **₹1,200 crore** revenue and **18%** net margin may not reflect underlying challenges.\n\n📊 *STOCKS:* ASTRAZEN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
AstraZeneca Pharma India attracts investor attention on NSE.
*AstraZeneca Pharma India attracts investor attention on NSE.* The stock has seen increased retail participation due to steady performance and stable margins. **₹923 crore** market cap and consistent dividend history bolster interest. No major corporate action reported recently. 📊 *STOCKS:* ASTRAZEN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
About AstraZeneca Pharma India Limited
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]
Healthcare · Pharmaceuticals & Biotechnology